button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC) 2 certainty unassessablestatistically conclusive-27% certainty unassessablestatistically conclusive-29%-

mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative

versus Standard of Care (SoC)
nivolumab plus SoC vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-18% certainty unassessable-21%-

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab alone vs. placebo plus SoC 1 certainty unassessable-29% certainty unassessable+10%-
pembrolizumab plus SoC vs. placebo plus SoC 2 certainty unassessable-14% certainty unassessable-15%-
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessable-8% certainty unassessable+66%-

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus paclitaxel
avelumab alone vs. paclitaxel 1 certainty unassessable+10% certainty unassessable+73%-
pembrolizumab alone vs. paclitaxel 1 certainty unassessable-6% certainty unassessable+49%-
versus placebo
nivolumab alone vs. placebo 1 certainty unassessable-34% certainty unassessable-37%-
versus Standard of Care (SoC)
Ipilimumab (10 mg/kg) vs. Standard of Care (SoC) 1 certainty unassessable+54% certainty unassessable+59%-

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive

versus paclitaxel
pembrolizumab alone vs. paclitaxel 1 certainty unassessable-17% certainty unassessable+27%-

mGC or mGEJC - M - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 negative

versus Standard of Care (SoC)
avelumab alone vs. Standard of Care (SoC) 1 certainty unassessable-8% certainty unassessable+4%-

mGC or mGEJC - M - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - maintenance (M) mGC or mGEJC - M - HER2 neg/PDL1 positive

versus Standard of Care (SoC)
avelumab alone vs. Standard of Care (SoC) 1 certainty unassessable+13% certainty unassessable+4%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons